CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. - sprookjes - yvandenbroek - TriplyDB

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q37058114

about

A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma The next generation of novel therapies for the management of relapsed multiple myeloma.Carfilzomib boosted combination therapy for relapsed multiple myeloma Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.How is patient care for multiple myeloma advancing?Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Emerging drugs and combinations to treat multiple myeloma.Proteasome-associated deubiquitinases and cancer.Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.An overview of the role of carfilzomib in the treatment of multiple myeloma.Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials.PSMD4 is a novel therapeutic target in chemoresistant colorectal cancer activated by cytoplasmic localization of Nrf2.Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)Carfilzomib for treating myeloma Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial

P2860

Q28067148-FBC1874F-6DDE-4714-B00D-4C033D871921 Q30248534-1033EFB2-52B5-40DE-BA81-1E7467C78734 Q37652953-3D71A972-B451-4920-9935-7487E4DB202F Q38672091-94E26354-8B51-494E-81D4-4301DB34E08F Q38685108-3530CAF1-A435-4D80-82AD-9536EF9BBC88 Q38786149-3CAB2C51-779C-4043-8077-3D17F19006B8 Q39234159-BF92308A-96C8-4B5A-9743-8EBC9F0F69D9 Q41694198-A5590BD3-952F-471C-BDCA-7CD31E56A4F8 Q47161331-87BAEF50-2B49-4DF0-A328-B7A87E4100E3 Q47236245-BEA745DA-6E9C-4648-B6A3-734EB391F2D0 Q48373422-4D7F8E61-ADD1-4B5A-9879-92CEC12DA15D Q49846557-04A71860-714F-4176-AFDF-4639B62AAE8F Q50035012-EF3524F4-3274-4D7B-90E5-1803A59D4AED Q55279720-9ADBE2B4-54C6-4CCC-AABA-78229AB4FCA4 Q55400650-5378B5DE-4D28-449E-BA43-967B2F11AC62 Q56362782-0C3CAC6E-F1AB-4CB2-B1B8-8CF475CDB04C Q57904173-7874C405-27B8-41DB-A12E-9C0126FA51EF Q58762364-644141A6-D5CC-45F6-BBFE-6488B604BCC9

P2860

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q37058114

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CHAMPION-1: a phase 1/2 study ...... r refractory multiple myeloma.

@en

CHAMPION-1: a phase 1/2 study ...... r refractory multiple myeloma.

@nl

type

label

CHAMPION-1: a phase 1/2 study ...... r refractory multiple myeloma.

@en

CHAMPION-1: a phase 1/2 study ...... r refractory multiple myeloma.

@nl

prefLabel

CHAMPION-1: a phase 1/2 study ...... r refractory multiple myeloma.

@en

CHAMPION-1: a phase 1/2 study ...... r refractory multiple myeloma.

@nl

P1433

Q37058114-E03CF889-15CF-4F7B-B2AB-DD55343EA837

P1476

Q37058114-05277D5E-C04B-4132-8AD6-217AF439241C

P2093

Q37058114-2E8A1FD8-984C-4981-AD65-3312566F0648

Q37058114-3081DECC-25CB-4852-A60A-69C41AE54E04

Q37058114-32492BA0-CB29-4FD4-B45C-80D17D11F4CE

Q37058114-40A395AA-B8D5-4C2B-917F-4F7E9213B0D1

Q37058114-57BD0E55-9F29-4CCB-9A9E-2362D243AC96

Q37058114-5E7C7605-11D3-4DF9-BB14-1BCA076A3CDF

Q37058114-62981AAA-03A9-48B1-8FDC-32E20C0F4E94

Q37058114-648429D1-2D4C-4924-85E5-FD08511387C6

Q37058114-75899665-5821-4D36-816C-2B2712F98C4C

Q37058114-80BAE3FF-0113-4EFA-ADED-58E43B04059B

P2860

Q37058114-0592D0E8-35BE-48EA-9B2F-B33516A28074

Q37058114-2B88C66F-61FA-41E0-B005-654370C00AF1

Q37058114-318D6AC8-D2E9-4EF4-9891-DB90719A9882

Q37058114-409F1D0B-A294-4DC8-998F-7AEF96C3C572

Q37058114-52678BF7-9916-473A-93BB-C0F7CBB03E5A

Q37058114-825C3E15-6579-493D-B291-3D1554FB1B80

Q37058114-9BD970C8-8D49-4409-9B3C-CA22D6776050

Q37058114-9C9F20E9-55C4-4F87-84C6-A6054D705C6F

Q37058114-9FC3963B-ED99-42F5-9D7B-0C2697895D4A

Q37058114-A84183D3-22BD-42B1-B642-009F69CFE4BE

P304

Q37058114-F91AE2C0-4543-453E-A931-AA4420D651B1

P31

Q37058114-7B8F2009-DFF4-4277-91B3-4BADF70051F2

P356

Q37058114-35886238-34B9-46B0-895E-1B9CB69D20DF

P407

Q37058114-FC150150-9FD3-4292-874D-461300392139

P433

Q37058114-3A7166D5-E8CB-4231-966D-60BD146FE270

P478

Q37058114-A53D7DC1-421D-4516-8AA7-C6EC1439E108

P577

Q37058114-B5EB497B-0756-4C07-ADC9-09CC71B51A37

P698

Q37058114-835A3AFA-A10E-4B3A-988A-3477A075131E

P921

Q37058114-0CF852FE-C9E4-4611-A5FD-F291D1B79415

P932

Q37058114-7F7BA87D-E41A-4EA1-AD24-1DFF637154A1

P356

BLOOD-2015-11-683854

P1433

P1476

CHAMPION-1: a phase 1/2 study ...... r refractory multiple myeloma.

@en

P2093

Alan Cartmell

http://www.w3.org/2001/XMLSchema#string

Alberto Bessudo

http://www.w3.org/2001/XMLSchema#string

Dimitrios Tzachanis

http://www.w3.org/2001/XMLSchema#string

James R Berenson

http://www.w3.org/2001/XMLSchema#string

Janet Anderl

http://www.w3.org/2001/XMLSchema#string

Jesus G Berdeja

http://www.w3.org/2001/XMLSchema#string

Morton Coleman

http://www.w3.org/2001/XMLSchema#string

Priti Patel

http://www.w3.org/2001/XMLSchema#string

Ralph Boccia

http://www.w3.org/2001/XMLSchema#string

Richy Agajanian

http://www.w3.org/2001/XMLSchema#string

P2860

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

P304

3360-3368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2015-11-683854

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27207788

http://www.w3.org/2001/XMLSchema#string

P921

P932

4929927

http://www.w3.org/2001/XMLSchema#string